Fourth EUCAST steering committee meeting
Summary of minutes of meeting in Copenhagen, Denmark, 2 September 2003

Attending
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom
Dr Claude-James Soussy C-JS SFM France
Dr Gunnar Kahlmeter GK Chairperson Sweden
Prof Alasdair P. MacGowan AM BSAC United Kingdom
Dr Johan W. Mouton JM CRG The Netherlands
Dr Anders Österlund AO SRGA Sweden
Dr Arne Rodloff AR DIN Germany
Dr Martin Steinbakk MS NWGA Norway
Dr Pavla Urbaskova PU EUCAST Czech Republic
Dr Alkiviadis Vatopoulos AV EUCAST Greece

Apologies
Dr Fred Goldstein FG SFM France

1 Chairman’s welcome and report. There is good progress with EMEA regarding official acknowledgement of EUCAST and the International Society of Chemotherapy have recognised EUCAST.

Comments received indicate that the Glasgow ECCMID was a success for EUCAST.

The EUCAST symposium at the ECCMID in Prague in May 2004 is finalised.

In order to improve communication with industry it is proposed to replace industry representatives on the General Committee with email groups.

A report on the NCCLS meeting in June 2003 was presented by GK.

2 Minutes of meeting of 9 May 2003 were accepted as a correct record.

3 Matters arising from minutes of 9 May 2003. It was accepted that statistical methods are not appropriate for defining the distribution of MICs for the wild type susceptible population because the MIC distribution is discontinuous.

4 Minutes of General Committee Meeting, 12 May 2003, Glasgow, UK will be distributed and placed on the EUCAST website.

5 Breakpoint procedure document. Modifications to the draft document were accepted. Further development is in progress.

6 Breakpoint tables on the internet. Agreed that the term “general breakpoint” would be replaced by “non-species-related breakpoint” and that a clear definition of the meaning be provided in a footnote to tables.

7 Quinolone breakpoints. Agreed to remove pefloxacin, enoxacin, gemifloxacin, gatifloxacin and garenoxacin from tables for the present.

Comments received on proposed EUCAST quinolone breakpoints have been tabulated and responses are being drafted in the light of proposed breakpoints, which were extensively reviewed.

8 Glycopeptide breakpoints. The table of proposed breakpoints was revised.

9 Linezolid breakpoints. The table of proposed breakpoints was revised.
10 **Aminoglycoside breakpoints.** Proposals for breakpoints will be distributed to the Steering Committee.

11 **Wild type distribution software** A program to input data has been developed and data are being received from a worldwide range of sources.

   The wild type distributions for, glycopeptides, linezolid and aminoglycosides will be made available on the public website (fluoroquinolones already available).

12 **CEN.** A draft microdilution method based on the EUCAST method was close to release for consultation. There is a proposal to take the CEN document on to an ISO document.

13 **EMEA guidance note on evaluation of medicinal products.** EUCAST is mentioned and the suggested format for susceptibility breakpoints is R>x mg/L.

14 **EUCAST documents.** Broth microdilution and yeast susceptibility testing discussion documents appeared as inserts in the August 2003 issue of CMI.

15 **Finances.** Response to the application to DG-SANCO had been positive.

16 **Declarations of interests of Steering Committee members** would be provided to the ESCMID Executive who would be asked to consider access to the information.

17 **Next meeting** 17-18 November 2003, Copenhagen

Ratified at Steering Committee meeting on 18 November 2003